| Identification | Back Directory | [Name]
1,3-Benzenediamine, N1,N1-dimethyl-N3-[6-phenyl-2-(4-piperidinyl)-4-pyrimidinyl]- | [CAS]
2248691-29-2 | [Synonyms]
1,3-Benzenediamine, N1,N1-dimethyl-N3-[6-phenyl-2-(4-piperidinyl)-4-pyrimidinyl]- | [Molecular Formula]
C23H27N5 | [MOL File]
2248691-29-2.mol | [Molecular Weight]
373.49 |
| Chemical Properties | Back Directory | [Boiling point ]
576.6±50.0 °C(Predicted) | [density ]
1.158±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9.51±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
ARN22089 is a oral active novel class of trisubstituted pyrimidine, blocks the interaction of CDC42 GTPases with specific downstream effectors. ARN22089 blocks tumor growth in BRAF mutant mouse melanoma model[1]. | [References]
[1] Brindani N, et al. Design, Synthesis, In Vitro and In Vivo Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer. J Med Chem. 2023;66(8):5981-6001. DOI:10.1021/acs.jmedchem.3c00276 |
|
|